The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
What is the benefit from second- and third-line (2L and 3L) therapy for extensive disease small cell lung cancer (ED-SCLC)? A prospective study of patterns, discontinuation, and survival in US community practices.
 
Donald A. Richards
Consulting or Advisory Role - Boehringer Ingelheim; Insys Therapeutics; IntegraGen; Lilly; Merrimack; Pharmacyclics
Speakers' Bureau - Celgene
 
Maen A. Hussein
Stock and Other Ownership Interests - Celgene
Speakers' Bureau - AMAG Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis
 
Steven L. McCune
Research Funding - Bristol-Myers Squibb (Inst)
 
Brian Kent Ulrich
No Relationships to Disclose
 
Bijoy PanKaj Telivala
Research Funding - AstraZeneca; Bristol-Myers Squibb; Incyte; Medevation; Pfizer; Pharmacyclics; Roche/Genentech
 
Marc Monte
Research Funding - Amgen; Amgen (Inst); Biodesix; Biodesix (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Celgene; Celgene (Inst); Incyte; Incyte (Inst); Janssen; Janssen (Inst); Lilly; Lilly (Inst); Pharmacyclics; Pharmacyclics (Inst); Seagen; Seagen (Inst); TG Therapeutics; TG Therapeutics (Inst)
 
Mark D. Danese
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); Genentech (Inst); Global Blood Therapeutics (Inst); GRAIL (Inst); Myriad Pharmaceuticals (Inst); Novartis (Inst); Portola Pharmaceuticals (Inst); Puma Biotechnology (Inst); Veracyte (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb; Celgene (Inst); EMD Serono (Inst); Genentech (Inst); Global Blood Therapeutics (Inst); GRAIL (Inst); Myriad Pharmaceuticals (Inst); Novartis (Inst); Portola Pharmaceuticals (Inst); Puma Biotechnology (Inst); Veracyte (Inst)
 
Michelle L. Gleeson
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Deborah P. Lubeck
Employment - Outcomes Insights
Stock and Other Ownership Interests - Amgen
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
 
Jenine Sanzari
Employment - Bristol-Myers Squibb
 
John R. Penrod
Employment - Bristol-Myers Squibb
 
Yong Yuan
Employment - Bristol-Myers Squibb
 
Pranav Abraham
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Beata Korytowsky
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Lee Steven Schwartzberg
Honoraria - Amgen; NanoString Technologies; Novartis; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Genomic Health; Helsinn Therapeutics; Pfizer; Spectrum Pharmaceuticals; Tesaro